Zila Pharmaceuticals’ “Next Generation” ViziLite Plus with TBlue630 Features New Pearlescent™ Retractor
ViziLite® Plus with TBlue630, the emerging standard of care for the early detection of oral abnormalities that could lead to cancer, now includes Pearlescent™ retractors, replacing the earlier transparent devices. With an opaque backside, the new retractors . . .
Zila Pharmaceuticals’ “Next Generation” ViziLite Plus with TBlue630 Features New Pearlescent™ Retractor
Phoenix, AZ – ViziLite® Plus with TBlue630, the emerging standard of care for the early detection of oral abnormalities that could lead to cancer, now includes Pearlescent™ retractors, replacing the earlier transparent devices. With an opaque backside, the new retractors focus more light on the oral cavity, and block light from shining directly back at the clinician.
“Dentists are having considerable success with ViziLite Plus,” said David Barshis, vice president and general manager of Zila Pharmaceuticals. “We are delighted to respond to their feedback with our new Pearlescent retractor, advancing this exciting, effective technology.”
Scottsdale, Arizona, dentist Paul Douglas has been using ViziLite Plus extensively. “My patients really appreciate the ViziLite Plus exam,” he said. “I provide it as part of nearly all routine annual exams. On several occasions, ViziLite helped identify areas of concern that otherwise would have been difficult, if not impossible, to find.”
ViziLite Plus is available from Pro-Dentec sales representatives and Zila Pharmaceuticals customer service representatives. Information is available at www.ViziLite.com, or 800-922-7887.
About Zila, Inc.
Zila, Inc., headquartered in Phoenix, is a leading oral cancer diagnostic company focused on the prevention and treatment of oral disease: Zila is dedicated to establishing ViziLite® Plus as the new standard of care for the early detection of oral abnormalities that could lead to cancer, with an initial focus on the dental market through Pro-Dentec®, a leading designer, manufacturer and marketer of Soft Tissue Management (STM®) products. Sold exclusively and directly to dental professionals, Pro-Dentec’s core products include the Rota-dent® Professional Powered Brush, the Pro-Select3® Piezo- Ultrasonic Scaler System and a suite of pharmaceutical STM® products for both in-office and home-care use. Zila is also focused on achieving regulatory approval for the next generation oral cancer diagnostic, OraTest®, followed by the development of additional applications of its cancer detection technologies. For more information about Zila, visit www.zila.com.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based largely on Zila’s expectations or forecasts of future events, can be affected by inaccurate assumptions and are subject to various business risks and known and unknown uncertainties, a number of which are beyond the Company’s control. Therefore, actual results could differ materially from the forward-looking statements contained herein. A wide variety of factors could cause or contribute to such differences and could adversely impact revenues, profitability, cash flows and capital needs. There can be no assurance that the forward-looking statements contained in this press release will, in fact, transpire or prove to be accurate. The Company makes no commitment, and disclaims any duty, to update or revise any forward-looking statements to reflect future events or changes in expectations. For a more detailed description of these and other cautionary factors that may affect Zila’s future results, please refer to Zila’s Form 10-K for its fiscal year ended July 31, 2006 and subsequent filings we make with the Securities and Exchange Commission.
<< Back
